Get the Stockscreener App
4.69
4.09%
-0.20
After Hours:
5.00
0.31
+6.61%
Curis Inc stock is traded at $4.69, with a volume of 135.85K.
It is down -4.09% in the last 24 hours and up +1,361% over the past month.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$4.89
Open:
$5.21
24h Volume:
135.85K
Relative Volume:
0.06
Market Cap:
$9.14M
Revenue:
$7.06M
Net Income/Loss:
$-21.17M
P/E Ratio:
-0.1964
EPS:
-23.879
Net Cash Flow:
$-28.95M
1W Performance:
+3.76%
1M Performance:
+1,361%
6M Performance:
+393.68%
1Y Performance:
+154.89%
1-Day Range:
$4.60
$5.30
1-Week Range:
$4.49
$5.50
52-Week Range:
$0.1806
$6.74
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
4.69 | 9.53M | 7.06M | -21.17M | -28.95M | -23.88 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
CRIS|Curis Inc|Price:5.190|Chg%:+0.300 - TradingKey
TradingKey - TradingKey
Curis Inc (CRIS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Curis Inc (CRIS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Curis Inc (CRIS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRIS Maintained by HC Wainwright & Co. -- Price Target Raised to $43.00 - GuruFocus
Curis, Inc. Revenue Breakdown – NASDAQ:CRIS - TradingView
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Benzinga
Curis Inc (CRIS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CRIS Q2'26 Earnings: revenue estimate is 1.00M USD - TradingView
Curis stock jumps 11% on positive emavusertib trial data - Investing.com
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Benzinga
Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus - Yahoo Finance
Curis Q2 2026: Updated Clinical Data for Emavusertib Trials - grafa.com
Curis stock jumps 11% on positive emavusertib trial data By Investing.com - Investing.com South Africa
Curis Inc Positive Emavusertib Update Transcript - GuruFocus
Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS) - Yahoo Finance
Curis reports updated trial data for emavusertib in lymphoma By Investing.com - Investing.com Nigeria
Curis reports updated trial data for emavusertib in lymphoma - Investing.com
Curis Announces Positive Emavusertib Update - PR Newswire
Why did Curis (CRIS) stock soar after hours? - MSN
FRA:CUS1 EPS (Basic): €-20.76 | Significantly Overvalued - GuruFocus
Curis (FRA:CUS1) Graham Number : €N/A (As of Mar. 2026) - GuruFocus
Curis Inc Annual Shareholders Meeting Transcript - GuruFocus
Curis (FRA:CUS1) Marketable Securities : €0.00 Mil (As of Mar. 2026) - GuruFocus
FRA:CUS1 EV-to-EBITDA: 0.69 — 35% Above Median - GuruFocus
Q2 2025 Curis Inc Earnings Call Transcript - GuruFocus
Q1 2026 Curis Inc Earnings Call Transcript - GuruFocus
Q3 2025 Curis Inc Earnings Call Transcript - GuruFocus
Curis Inc (FRA:CUS1) Stock Price & 30 Year Financial Data - GuruFocus
Curis Inc (FRA:CUS1)Valuation Measures & Financial Statistics - GuruFocus
Curis Inc (FRA:CUS1) Stock Earnings Transcripts - GuruFocus
Curis Inc (FRA:CUS1) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Equity in earnings of Curis, Inc. – SWB:CUS1 - TradingView
Price to book forward of Curis, Inc. – SWB:CUS1 - TradingView
Long term debt to total equity ratio of Curis, Inc. – SWB:CUS1 - TradingView
Curis Inc. (CRIS) Holds Near Support Amid Slight Uptick – Key Levels in FocusDividend Stock Picks - dars.gov.et
Net margin % of Curis, Inc. – DUS:CUS1 - TradingView
Net current asset value per share of Curis, Inc. – DUS:CUS1 - TradingView
Form 4 Curis Inc For: 9 July By Investing.com - Investing.com Nigeria
Director Marc Rubin receives 6,800 Curis (CRIS) stock options at $5.29 - Stock Titan
Curis (CRIS) director receives grant of 6,800 non-qualified stock options - Stock Titan
Curis (CRIS) director John Hohneker receives 6,800 stock options at $5.29 - Stock Titan
Curis Inc (CRIS) director receives 6,800 stock options at $5.29 - Stock Titan
CURIS INC (CRIS) director granted 6,800 non-qualified stock options at $5.29 - Stock Titan
CURIS (CRIS) CFO receives 48,285 stock options at $5.29 exercise price - Stock Titan
Curis (CRIS) CDO Jonathan Zung receives 48,285 stock options at $5.29 strike - Stock Titan
Curis (CRIS) CEO receives 110,090 employee stock options at $5.29 - Stock Titan
Price to book forward of Curis, Inc. – HAM:CUS1 - TradingView
Return on invested capital % of Curis, Inc. – HAM:CUS1 - TradingView
Net income of Curis, Inc. – HAM:CUS1 - TradingView
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):